Evidence map›Paper›PMID 40578498›Full record

ArticleThe journal of pain2025

Opposing effects of mu opioid receptors on dopamine D1 and D2 receptor expressing neurons in opioid mediated antinociception.

Jacob Alderete, Anthony Tanzillo, Jason Miller, Lorna Barrall, Hazem Nasef, Emily Ellis, Gabriella Sigal, Flora D 'Oliveira Da Silva, Merel Dagher, Christopher J Evans and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of pain, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Adenosine AFrontiers in pharmacology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jacob AldereteShirley and Stefan Hatos Center for Neuropharmacology, Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA, United States.
Anthony TanzilloShirley and Stefan Hatos Center for Neuropharmacology, Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA, United States.
Jason MillerShirley and Stefan Hatos Center for Neuropharmacology, Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA, United States.
Lorna BarrallShirley and Stefan Hatos Center for Neuropharmacology, Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA, United States.
Hazem NasefShirley and Stefan Hatos Center for Neuropharmacology, Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA, United States.
Emily EllisShirley and Stefan Hatos Center for Neuropharmacology, Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA, United States.
Gabriella SigalShirley and Stefan Hatos Center for Neuropharmacology, Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA, United States.
Flora D 'Oliveira Da SilvaShirley and Stefan Hatos Center for Neuropharmacology, Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA, United States; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.
Merel DagherDepartment of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.
Christopher J EvansShirley and Stefan Hatos Center for Neuropharmacology, Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA, United States; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States; Brain Research Institute, University of California, Los Angeles, Los Angeles, CA, United States.
Catherine M CahillShirley and Stefan Hatos Center for Neuropharmacology, Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA, United States; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States; Brain Research Institute, University of California, Los Angeles, Los Angeles, CA, United States. Electronic address: cmcahill@ucla.edu.

Funding

The Role of Striosome Neurons in Mediating Opiod RewardP50DA005010 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI YANG, XIANGDONG WILLIAM · 1987 to 2021
$30.7M
UCLA IDDRC: Translational CoreP50HD103557 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SUSAN Y BOOKHEIMER · 2020 to 2026
$9.6M
Amygdala kappa opioid system involvement in opioid relapse in pain statesR01DA053752 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CATHERINE M CAHILL · 2022 to 2026
$2.8M
NICHD NIH HHS P50 HD103557NIDA NIH HHS P50 DA005010NIDA NIH HHS R01 DA053752
6 · The paper itself

Abstract

There is extensive interaction between systems involved in pain processing and motivation, where the aberrant functioning of salience circuits likely contributes to chronic pain, as well as increased susceptibility to opioid misuse and opioid use disorder. This study asks to what extent mu opioid receptors (MORs) in dopamine D1 receptor (D1R), D2 receptor (D2R) or adenosine A2a receptor (A2aR) expressing neurons contribute to the expression of pain and opioid antinociception. We ablated MORs in dopamine receptor expressing neurons by breeding D1R, D2R or A2aR-cre with MOR

Indexed as

Analgesics, OpioidNeuronsNociceptionOxycodoneReceptors, Dopamine D1Receptors, Dopamine D2Receptors, Opioid, muAnimalsMaleMiceMice, Inbred C57BLMice, TransgenicReceptor, Adenosine A2AAnalgesics, OpioidDrd1 protein, mouseDRD2 protein, mouseOxycodoneReceptor, Adenosine A2AReceptors, Dopamine D1Receptors, Dopamine D2Receptors, Opioid, muAnalgesiaAntinociceptionDopamineDopamine receptorFormalin testMedium spiny neuronMorphineNeuropathic painOpiateOpioidPainStriatumThermal pain

Identifiers

PMID40578498
PMCPMC13479386

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.